According to the Zhitong Finance App, Laimei Pharmaceutical (300006.SZ) announced that the board of directors of the company requested the shareholders' meeting to authorize the board of directors to fully handle matters relating to the issuance of shares to specific targets through simplified procedures. The authorization period is from the date of approval of the 2022 Annual General Meeting of Shareholders to the date of the 2023 Annual General Meeting of Shareholders. The issuance price is not less than 80% of the average stock transaction price for the 20 trading days prior to the pricing benchmark date. The total amount of capital raised in this issue does not exceed 300 million yuan and does not exceed 20% of net assets at the end of the last year.
Laimei Pharmaceutical (300006.SZ) plans a simplified procedure to raise no more than 300 million yuan
This page is machine-translated. Futubull tries to improve but do not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation.
Risk disclosure: The above content only represents the opinion of the authors or guests, and does not represent any positions of Futu or constitute any investment advice on the part of Futu. Before making any investment decision, investors should consider the risk factors related to investment products based on their own circumstances and consult professional investment advisers where necessary. Futu makes every effort to verify the authenticity, accuracy, and originality of the above content, but does not make any guarantees or promises.